References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2018-3-105-115

vtio-919

Research Article

Обзор литературы

Literature Reviews

Противовирусная терапия гепатита С 1 генотипа после трансплантации печени

Antiviral therapy of hepatitis C with 1 genotype after liver transplantation

Цирульникова

О. М.

Tsiroulnikova

O. M.

Умрик

Д. В.

Umrik

D. V.

Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (926) 434-16-24

Address: 1, Shchukinskaya st., Moscow, 123182, Russian Federation. Tel. (926) 434-16-24

d_ipatova@mail.ru

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский университет)РоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of the Russian Federation (Sechenovsky University)Russian Federation

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian Federation

2018

17092018

203105115

2018

Цирульникова О.М., Умрик Д.В.

Tsiroulnikova O.M., Umrik D.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/919

Хроническая HCV-инфекция является ведущей причиной трансплантации печени взрослым в развитых странах. К сожалению, реинфицирование трансплантата неизбежно происходит у всех пациентов с сохраняющейся репликацией вируса. На фоне необходимой иммуносупрессивной терапии прогрессирование заболевания ускоряется, приводя к быстрой декомпенсации печени. Проведение противовирусной терапии значительно улучшает результаты трансплантации, однако применение стандартных схем на основе интерферона сопряжено с низкой эффективностью (не более 30% для наиболее распространенного 1-го генотипа вируса) и плохой переносимостью. В статье описаны новые безинтерфероновые пероральные режимы терапии, применяемые для лечения рецидива HCV-инфекции 1-го генотипа.

Chronic HCV infection is the leading cause of liver transplantation in adults in developed countries. Unfortunately, the reinfection of the graft inevitably occurs in all patients with persistent replication of the virus. Against the background of the necessary immunosuppressive therapy, the progression of the disease accelerates, leading to rapid decompensation of the liver. Antiviral therapy significantly improves the results of transplantation, but the use of standard interferon-based regimens is associated with low efficacy (no more than 30% for the most common 1 genotype of the virus) and poor tolerance. The article describes new interferon- free oral regimens used to treat the recurrence of HCV infection of 1 genotype.

хронический гепатит Срецидивтрансплантация печенипрепараты прямого противовирусного действияустойчивый вирусологический ответ

chronic hepatitis Crelapseliver transplantationdirect antiviral actionresistant virologic response.

References1

Всемирная организация здравоохранения [Internet]. Информационный бюллетень. Гепатит С; 2 октября 2017 г. Vsemirnaya organizaciya zdravoohraneniya [Internet]. Informacionnyj byulleten’. Gepatit C; 2 oktyabrya 2017 g. http://www.who.int/ru/news-room/factsheets/detail/hepatitis-c.

Bunchorntavakul C, Reddy KR. Management of hepatitis C before and after liver transplantation in the era of rapidly evolving therapeutic advances. J. Clin. Transl. Hepatol. 2014; 2: 124–133.

Hedskog C, Bhardwaj N, Chang S, Parhy B, Martin R, Zeuzem S et al. Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens. Reported by Jules Levin. AASLD: The Liver Meeting® 2017, October 20–24, 2017, Washington, DC.

Simmonds P, Becher P, Collett M et al. Family Flaviviridae In: Virus Taxonomy: Ninth report of the International Committee on taxonomy of viruses. Elsevier Science. 2011: 1003–1020.

Орлов СТ, Неверов АД, Михайловская ГВ. Разработка и апробация тест-системы «АмплиСенс HCV-генотип FRT» на клиническом материале и контрольных панелях QCMD. Сборник трудов 6-й Всероссийской НПК с международным участием «Молекулярная диагностика-2007». 2007; 1: 320–323. Orlov ST, Neverov AD, Mihajlovskaya GV. Razrabotka i aprobaciya test-sistemy «AmpliSens HCV-genotip FRT» na klinicheskom materiale i kontrol’nyh panelyah QCMD. Sbornik trudov 6-j Vserossijskoj NPK s mezhdunarodnym uchastiem «Molekulyarnaya diagnostika-2007». 2007; 1: 320–323.

Klempnauer J, Castaing D, Neuhaus P et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J. Hepatol. 2012; 57: 675–688.

Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999–2008. Am. J. Transplant. 2010; 10: 1003–1019.

Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680–687.

Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol. Int. 2016 Sep; 10 (5): 749–761.

Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect. Dis. 2016 Jun; 16 (6): 735–745.

Франк ГА, Ивашкин ВТ, Лукина ЕА и др. Вирус гепатита С в клетках крови и костного мозга у больных с неясными гематологическими синдромами. Гематология и трансфузиология. 2000; 5: 13–17. Frank GA, Ivashkin VT, Lukina EA i dr. Virus gepatita C v kletkah krovi i kostnogo mozga u bol’nyh s neyasnymi gematologicheskimi sindromami. Gematologiya i transfuziologiya. 2000; 5: 13–17.

Grassi A, Ballardini G. Post-liver transplant hepatitis C virus recurrence: An unresolved thorny problem. World Journal of Gastroenterology : WJG. 2014; 20 (32): 11095–11115. DOI: 10.3748/wjg.v20.i32.11095.

Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 14 (Suppl 2): 36–44. DOI: 10.1002/lt.21646.

Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayón M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 2000; 32: 673–684.

Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl. 2009; 15: 1063–1071.

Hori T, Onishi Y, Kamei H et al. Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma. The American Journal of Case Reports. 2016; 17: 597–604. DOI: 10.12659/AJCR.898427.

European Liver Transplant Registry [Internet]. http://www.eltr.org/ Patient Survival vs Primary Indication. Available from: http://www.eltr.org/Overall-indicationand-results.html.

Song ATW, Sobesky R, Vinaixa C et al. Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World Journal of Gastroenterology. 2016; 22 (18): 4547–4558. DOI: 10.3748/wjg.v22.i18.4547.

Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl. 2003; 9: 897–904/.

Roayaie S, Schiano TD, Thung SN, Emre SH, Fishbein TM, Miller CM et al. Results of retransplantation for recurrent hepatitis C. Hepatology. 2003; 38: 1428–1436.

Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005; 11: 434–440.

Selzner N, Renner E, Selzner M et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009; 88: 1214–1221.

Veldt BJ, Poterucha JJ, Watt KD et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am. J. Transplant. 2008; 8: 2426–2433.

Carrión JA, Navasa M, García-Retortillo M et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology. 2007; 132: 1746–1756.

Belli LS et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. Journal of Hepatology. 2016; 65 (3): 524– 553.

Guidelines. EASL Recommendations on Treatment of Hepatitis C 2016. European Association for the Studyof the Liver. Journal of Hepatology. 2017; 66: 153–194.

EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology. 2016; 64 (2): 433–485.

Pawlotsky, Jean-Michel et al. EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology. 2018.

Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008; 14: 58–66.

Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012; 142: 1373–1383.

Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am. J. Transplant. 2006; 6 (7): 1586–1599.

Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 2008; 49: 274– 287. DOI: 10.1016/j.jhep.2008.05.002.

Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso A, Delvart V et al. Hepatitis C virus therapy in liver transplant recipients: Response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766–1777. DOI: 10.1002/lt.21635.

Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002: 237–244.

Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013; 19: 837–849.

Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med 2011; 364: 2405–2416.

Zeuzem S, Andreone P, Pol S et al. REALIZE Study Team. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 2011; 364 (25): 2417–2428. DOI: 10.1056/NEJMoa1013086.

Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010; 376: 705–716.

Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195–1206.

Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1207–17.

Hulskotte E, Gupta S, Xuan F, van Zutven M, O‘Mara E, Feng H et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012; 56: 1622–1630.

Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology. 2011; 54: 20–27.

Pungpapong S, Aqel BA, Koning L et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19 (7): 690–700.

Coilly A, Dumortier J, Botta-Fridlund D et al. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? Yu M-L, ed. PLoS ONE. 2015; 10 (9): e0138091. DOI: 10.1371/journal.pone.0138091.

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW et al. Protease inhibitor- based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann. Hepatol. 2014; 13: 525–532.

Burton JR Jr, O’Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease- inhibitor triple therapy. J. Hepatol. 2014; 61: 508–514. DOI: 10.1016/j.jhep.2014.04.037 [PMC free article] [PubMed].

Werner CR, Egetemeyr DP, Nadalin S, Konigsrainer A, Malek NP, Lauer UM et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z. Gastroenterol. 2014; 52: 27–34. DOI: 10.1055/s-0033-1356345.

Jacobson IM et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo- controlled trial. The Lancet. 2014; 384 (9941): 403–413.

Forns X, Lawitz E, Zeuzem S et al. Simeprevir (TMC435) with peginterferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub- populations in the PROMISE Phase III trial [abstract]. Hepatology. 2013; 58 (1): 737.

Ueda Y, Ikegami T, Soyama et al. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience. Hepatol. Res. 2016; 46: 1285–1293. DOI: 10.1111/hepr.12684.

Shinoda M et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatology Research. 2016; 46 (11): 1118–1128.

Charlton M et al. Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. Gastroenterology. 2015; 148 (1): 108–117.

Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015; 61 (6): 1880–1886.

Brown RS, O’Leary JG, Reddy KR et al. Interferon-free Therapy for Genotype 1 Hepatitis C in Liver Transplant Recipients: Real World Experience from HCV-TARGET. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2016; 22 (1): 24–33. DOI: 10.1002/lt.24366.

Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Martin P, Bhamidimarri KR et al. Sofosbuvir and Simeprevir for Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. Liver Transpl. 2015.

Pyrsopoulos N et al. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. European Journal of Gastroenterology & Hepatology. 2018; 30 (7): 761–765, DOI: 10.1097/MEG.0000000000001101 [abstract].

Leroy VP, Georges-Philippe et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clinical Gastroenterology and Hepatology. 2015; 13 (11): 1993–2001.

Poordad F, Schiff ER, Vierling JM et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63 (5): 1493–1505. DOI: 10.1002/hep.28446.

Aragwal K et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. Journal of Hepatology. 2017; 6: 34 [abstract].

Anty R, Favre AG, Coilly E, Rossignol P, Houssel-Debry C, Duvoux V et al. Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. Hepatol. 2018. pii: S0168- 8278(18)32124-X. DOI: 10.1016/j.jhep.2018.05.039. [Epub ahead of print] https://doi.org/10.1111/apt.14639.

Tronina O, Durlik M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+ Dasabuvir ± Ribavirin (OBV/PTV/r/ + DSV ±RBV). Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBERCEE Study. Ann. Transplant. 2017; 22: 199–207. DOI: 10.12659/AOT.903535.

Ming-Lung Yu, Yao-Li Chen, Chung-Feng Huang, Kuo-Hua Lin, Ming-Lun Yeh, Ching-I. Huang. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real- world experience. Journal of the Formosan Medical Association. 2018; 117: 518–526.

Miuma S, Miyaaki H, Soyama A, Hidaka M, Takatsuki M, Shibata H et al. Utilization and efficacy of elbasvir/ grazoprevir for treating hepatitis C virus infection after liver transplantation. Hepatol. Res. 2018. DOI: 10.1111/hepr.13204.

Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P et al. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. Hepatology. 2018. DOI: 10.1002/hep.30046.

The authors declare that there are no conflicts of interest present.